Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 1,157 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $11.52, for a total value of $13,328.64. Following the completion of the transaction, the general counsel now owns 28,187 shares in the company, valued at approximately $324,714.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Benjamin Landry also recently made the following trade(s):
- On Friday, July 7th, Benjamin Landry sold 1,179 shares of Health Catalyst stock. The shares were sold at an average price of $11.14, for a total value of $13,134.06.
Health Catalyst Trading Up 4.0 %
Shares of HCAT stock opened at $11.91 on Thursday. The company has a market capitalization of $678.39 million, a PE ratio of -4.44 and a beta of 1.30. Health Catalyst, Inc. has a 52-week low of $6.40 and a 52-week high of $15.87. The business’s fifty day moving average is $12.46 and its 200 day moving average is $12.23. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.74 and a current ratio of 4.74.
Analyst Ratings Changes
HCAT has been the topic of several research reports. Cantor Fitzgerald initiated coverage on shares of Health Catalyst in a research report on Tuesday, August 1st. They issued an “overweight” rating and a $16.00 price objective on the stock. Raymond James cut Health Catalyst from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 10th. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, August 29th. Finally, Guggenheim lowered shares of Health Catalyst from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 10th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and a consensus price target of $14.55.
Institutional Trading of Health Catalyst
A number of hedge funds have recently made changes to their positions in the stock. Fairfield Bush & CO. bought a new stake in Health Catalyst in the 1st quarter worth approximately $25,000. Macquarie Group Ltd. purchased a new position in shares of Health Catalyst during the second quarter worth approximately $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Health Catalyst in the 1st quarter worth approximately $33,000. WealthPlan Investment Management LLC purchased a new stake in shares of Health Catalyst in the 1st quarter valued at $39,000. Finally, US Bancorp DE grew its holdings in shares of Health Catalyst by 36.5% during the 1st quarter. US Bancorp DE now owns 4,260 shares of the company’s stock valued at $50,000 after purchasing an additional 1,139 shares during the last quarter. 86.63% of the stock is owned by institutional investors.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases.
- Five stocks we like better than Health Catalyst
- How to Invest in Social Media
- These Quality Dividend Kings Grow their Dividends the Fastest
- How to Invest and Trade Chinese Stocks
- 3 Growth Stocks to Buy in September
- Business Services Stocks Investing
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.